Bioventus Q3 GAAP EPS $0.05 vs -$0.08 YoY; organic revenue +8% to $138.7M

Bioventus Inc.

2025-Q3 EPS reported $0.12 revenue$410,187,000

GAAP net income $3.2M vs $5.2M loss; diluted EPS $0.05 improved from -$0.08 YoY.
Non-GAAP EPS $0.15, up 200% from $0.05; Adjusted EBITDA $26.6M (+12.9%) with margin 19.2%.
Organic revenue growth 8.2% led by Pain Treatments (+6.4%) and Surgical Solutions (+9.3%).
Cash from operations $30.1M, +192% YoY; reaffirms FY2025 revenue $560-570M and Adj. EBITDA $112-116M.
Entered new credit agreement with $300M term loan and $100M revolver, reducing annual interest by ~$2M.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.